Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Merck And Pfizer Strike Generics Deals
by Rick Mullin
February 27, 2012
| A version of this story appeared in
Volume 90, Issue 9
Merck & Co. and Brazil’s Supera Farma Laboratorios have formed a joint venture to market pharmaceuticals and branded generics in Brazil. The partners will initially market approximately 30 products across multiple therapeutic areas. Meanwhile, Pfizer and Shanghai-based Hisun Pharmaceutical have advanced plans for a joint venture to commercialize off-patent drugs in China and other markets. Pfizer will own 49% of its joint venture with Hisun and invest $295 million in it. Merck will own 51% of its joint venture with Supera. Financial details of that deal were not disclosed.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter